Spotlight Growth
No Result
View All Result
Friday, March 31, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

FDA Issues Positive Pre-IND Response to Alzamend Neuro, Inc.’s (NASDAQ: ALZN) AL002 Candidate for Treatment of Alzheimer’s Disease

by admin
September 30, 2021
in Bio/Med/Pharma
0
Alzamend Neuro NASDAQ ALZN FDA Pre IND AL002 Spotlight Growth

Alzamend Neuro NASDAQ ALZN FDA Pre IND AL002 Spotlight Growth

Alzamend Neuro, Inc. (NASDAQ: ALZN) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of novel treatments for neurodegenerative diseases and psychiatric disorders. Shares of the biopharmaceutical company are surging 39% through afternoon trading on Thursday, September 30, 2021. Over the past three months, Alzamend Neuro has seen average daily volume of 2.09 million shares. However, volume of 46.66 million shares or dollar volume of $148.38 million, has already exchanged hands through Thursday’s afternoon trading.

Shares of Alzamend Neuro are rallying after the company announced that it has received a positive pre-IND response from the U.S. Food and Drug Administration (FDA) regarding its AL002 candidate. AL002 utilizes a mutant-peptide sensitized cell as a cell-based vaccine that is designed to restore a patient’s immunological system in order to fight Alzheimer’s.

The FDA’s response to the company’s Type B Pre-Investigational New Drug (IND) application provides a path forward for the company to continue clinical development of the candidate. With the FDA’s approval of Alzamend Neuro’s plans to conduct a combined Phase 1 and 2 clinical trial for AL002, the company estimates filing the IND by the end of November 2021. Initiation of the AL002 clinical trial is anticipated to begin sometime during the first quarter of 2022.

“We appreciate the thorough and meaningful response from the FDA, which provides us with the information and clarity needed to submit the IND application to initiate a clinical trial for AL002,” said Stephan Jackman, Alzamend’s Chief Executive Officer. “Preclinical work supports AL002 being associated with a positive anti-inflammatory response and a decrease in brain amyloid contents. Based on AL002’s positive toxicology results, the biologic nature of this product and the urgent need to deliver treatments for Alzheimer’s to patients, Alzamend proposed, and the FDA agreed, to conduct a combined Phase 1/2 study. We appreciate the FDA’s recommendations, guidance and other helpful advice. We plan to augment our proposed clinical trial protocols and proceed accordingly.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: Alzamend NeuroAlzamend Neuro stockAlzheimer'sALZNALZN stockbiopharmabiopharmaceuticalsbiotechbiotech stocksbiotechnologyclinical trialscommon stockemerging growthFDAinvestinginvesting newsinvestmentmedicalmedical treatmentmicrocap stocksNASDAQnewspharmaceuticalspre-IND filingpublic companyRobinhoodrobinhood stockssalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstockstradingtreatmenttreatment for Alzheimer'sUS FDAwallstreetbetswebullWSB
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Asure Software NASDAQ ASUR Partner Harbor Compliance Spotlight Growth

Asure Software (NASDAQ: ASUR) Partners with Harbor Compliance to Help SMBs Streamline Registration Compliance

March 30, 2023
EVgo NASDAQ EVGO FY 2022 and Q4 2022 Financial Results Spotlight Growth

EVgo (NASDAQ: EVGO) Shares Q4 and FY 2022 Financial Results Showing Massive Revenue Growth, Issues Guidance For 2023

March 30, 2023
SCYNEXIS Nasdaq SCYX GSK NYSE GSK Exclusive Agreement Fungal Infection Spotlight Growth

SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

March 30, 2023
Four Pillars of Financial Risk Management Spotlight Growth

The Four Pillars of Financial Risk Management

March 29, 2023

Recent News

Asure Software NASDAQ ASUR Partner Harbor Compliance Spotlight Growth

Asure Software (NASDAQ: ASUR) Partners with Harbor Compliance to Help SMBs Streamline Registration Compliance

March 30, 2023
EVgo NASDAQ EVGO FY 2022 and Q4 2022 Financial Results Spotlight Growth

EVgo (NASDAQ: EVGO) Shares Q4 and FY 2022 Financial Results Showing Massive Revenue Growth, Issues Guidance For 2023

March 30, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested